1. Home
  2. CFND vs CGTX Comparison

CFND vs CGTX Comparison

Compare CFND & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

N/A

Current Price

$3.80

Market Cap

27.4M

Sector

N/A

ML Signal

N/A

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.06

Market Cap

94.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFND
CGTX
Founded
N/A
2007
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.4M
94.5M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
CFND
CGTX
Price
$3.80
$1.06
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.33
AVG Volume (30 Days)
22.7K
581.5K
Earning Date
N/A
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.68
$0.22
52 Week High
$9.67
$3.83

Technical Indicators

Market Signals
Indicator
CFND
CGTX
Relative Strength Index (RSI) 43.21 43.79
Support Level $3.75 $1.00
Resistance Level $4.08 $1.19
Average True Range (ATR) 0.18 0.07
MACD 0.03 0.01
Stochastic Oscillator 40.28 27.78

Price Performance

Historical Comparison
CFND
CGTX

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: